Intensity Therapeutics Inc. (INTS)
(Delayed Data from NSDQ)
$0.28 USD
+0.01 (3.70%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $0.28 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INTS 0.28 +0.01(3.70%)
Will INTS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for INTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INTS
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
INTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INTS
Crossed Above 50 Day Moving Average appears for INTS after 3.7% move
Is INTS preparing to trend higher? Crossed Above 50 Day Moving Average shows up after rocketing 8.15%
Is INTS primed for upward momentum? Crossed Above 20 Day Moving Average shows up after rallying 6.22%
Technical picture remains unchanged for INTS after it falls 1.1% on September 30
12 Health Care Stocks Moving In Wednesday's Pre-Market Session